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ABSTRACT 
 
 Porcine Circovirus Type 2 Viral Protein 3 (PCV-2 VP3) is a homolog of the Chicken 
Anemia Virus protein Apoptin, a protein that can selectively target and kill cancer cells in a p53-
independent manner.  As many human cancers lack the p53 tumor suppressor, the discovery of 
p53-independent apoptotic pathways that lead to cancer cell destruction is of utmost importance 
for the development of new anticancer therapeutics.  PCV-2 VP3, like Apoptin, might engage in 
a pathway that is regulated by cellular localization.  Therefore, investigation of PCV-2 VP3’s 
sub-cellular localization patterns could elucidate the basis for its cancer cell specificity and 
apoptotic ability.  To that end, truncation mutants of the protein’s Nuclear Export Signal (NES) 
sequence and Nuclear Localization Signal (NLS) sequence were constructed for use in future 
cellular localization experiments.  In addition, the apoptotic ability of PCV-2 VP3 was assessed 
in a non-small cell lung carcinoma cell line, and this study demonstrates for the first time that 
PCV-2 VP3, like Apoptin, induces apoptosis in cancerous cells via a p53-independent pathway 
mediated by caspase-3/7.   
  
.          
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INTRODUCTION 
The Porcine Circoviruses 
The porcine circoviruses (PCVs) belong to the family Circoviridae, a group of unique 
viruses that include the smallest known viruses to replicate autonomously in a eukaryotic cell 
host (3).  Several avian viruses also belong to this viral family, including Psittacine beak-feather 
disease virus, goose circovirus, canary circovirus, pigeon circovirus, and chicken anemia virus 
(CAV).   Circoviruses are small, non-enveloped spherical viruses with circular, single-stranded 
DNA genomes, typically between 1,750 and 2,319 nucleotides in length.  This DNA is packaged 
into icosahedral protein capsids of 16-18 nm in diameter.   Differences in genomic organization 
and capsid morphology led to the creation of two distinct genera within the Circoviridae family: 
the Gyrovirus genus, of which CAV is the only member, and the Circovirus genus, of which 
PCV is a member (1).  
PCV was first identified and isolated in 1974 as a contaminant of cultured pig kidney 
cells (15).  It was later found to be widespread in swine, but caused no symptoms (4).  This 
particular virus was dubbed “PCV-1” after the 1991 discovery of another similar virus, “PCV-2,” 
that was found to be the causative agent of Postweaning Multisystemic Wasting Syndrome 
(PMWS), an acute illness in young pigs.  PMWS affects pigs between 5 and 18 weeks of age.  
Symptoms include progressive weight loss, dyspnea, anemia, diarrhea, and lymphoid lesions.  
Mortality rates vary between 1% to 30% depending on the severity of the particular case, and the 
disease has economically impacted the swine industry worldwide (4).   There are several 
differences between PCV-1 and PCV-2 at the nucleotide and amino acid levels, which likely 
account for the differing pathogenicity between them.  However, the basis of this distinct 
pathogenicity has yet to be determined (1). 
7 
 
The PCV-1 genome (1,759 nucleotides) is slightly smaller than that of PCV-2 (1,768 
nucleotides).  The overall DNA sequence homology within PCV-1 or PCV-2 isolates is greater 
than 90%, and the homology between PCV-1 and PCV-2 isolates is 68-76% (4).  The genomes 
of both PCV-1 and PCV-2 are ambisense and have two major Open Reading Frames (ORFs) and 
one minor ORF, as shown below in Figure 1.   
 
 
 
Figure 1.  The PCV Genome.  The PCV genome contains three open reading frames.   
 
The two main ORFs in the genome – ORF 1 and ORF 2 – code for proteins that perform 
the most elementary functions of a virus: genome replication and packaging.  Together, ORF 1 
and ORF 2 comprise 93% of the PCV genome (16).  The largest ORF in the genomes of both 
PCV-1 and PCV-2 is ORF 1; it encodes the rep gene which is responsible for the production of 
the Rep and Rep’ proteins that are necessary for viral replication. These proteins are produced 
from differentially-spliced transcripts (1).  The sequences for Rep and Rep’ are approximately 
80% homologous between PCV-1 and PCV-2.    
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ORF 2 encodes the major structural protein Cap, which is responsible for the structure of 
the immunogenic viral capsid.  PCV-1 and PCV-2 share a 62% homology at the nucleotide level 
with respect to ORF 2.  The capsids for PCV-1 and PCV-2 are similar in both size and shape, so 
a difference in tropism is an unlikely reason for the difference in pathogenicity between them.  
The icosahedral structure of the PCV-1 and PCV-2 virions is formed by the self-assembly of 60 
capsid protein molecules arranged in 12 flat, pentamer clustered units (22).  The capsid protein 
size varies slightly between PCV-1 and PCV-2; the protein encoded by PCV-1 ORF 2 is 36 kDa 
and the one encoded by PCV-2 is 30 kDa.  In addition to ORF 1 and ORF 2, the PCVs are 
predicted (through computer technology) to contain another five potential ORFs that encode 
proteins larger than 5 kDa (4).  Whether these potential ORFs are expressed and are necessary 
for successful viral replication has yet to be determined.  The largest among these is called ORF 
3.   
While Rep and Cap are required for the production of viral particles, the protein 
expressed by ORF 3 is not, yet PCV-2 ORF 3 has an important function in viral pathogenesis in 
vivo (4, 17).  ORF 3 for each serotype of PCV is dramatically different in size and sequence – 
612 base pairs in PCV-1 and 312 base pairs in PCV-2.  Moreover, the amino acid sequences 
coded by PCV-1 ORF 3 and PCV-2 ORF 3 are 61.5% homologous.  A 2005 study involving the 
infection of cells with ORF 3-deficient PCV-2 proved that the protein encoded by PCV-2 ORF 3 
(henceforth referred to as PCV-2 VP3) is not essential for viral replication (4). However, that 
same study demonstrated that PCV-2 VP3 is linked to the induction of apoptosis through a 
caspase pathway (4).  PCV-1 VP3 harbors no such documented activity, though studies are 
currently underway to determine its potential apoptotic capabilities (Heilman Lab, 2010).  Not 
only is PCV-2 VP3 a protein linked to apoptosis, it is responsible for causing PMWS (17).  It is 
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speculated, then, that the genetic permutations found in ORF 3 between the two PCV serotypes 
accounts for the differences in virulence in pigs.  
PCV-1 is the only non-pathogenic circovirus identified to date (1).  Conversely, it is 
interesting to note that even if a pig is infected with PCV-2, PMWS does not necessarily develop 
(16).  In 2004, the swine industry in Canada suffered from a sharpened increase in the swine 
deaths due to PMWS, well beyond the normal death rate for the disease.  Scientists formed 
several hypotheses for this occurrence, including the idea that a more virulent strain of PCV-2 
could be exacerbating the already present PMWS problem among the pig population.  Indeed, 
upon careful examination of the pigs and the viruses infecting them, two distinct forms of PCV-2 
were discovered: PCV-2a and PCV-2b.  It appeared that PCV-2b was affecting swine much more 
powerfully than PCV-2a (which was considered the ‘original’ virus) (18). These viruses have 
been compared on a molecular level to see if there are reasons to account for the variance in viral 
action between the two.  
Porcine Circovirus 2 Viral Protein 3 (PCV-2 VP3) 
The degree of homology between PCV-2a VP3 and PCV-2b VP3 is remarkable, but a 
drastic difference in pathogenicity among the pig population is observed. The gene alignment 
indicates a 98% homology at the nucleotide level. There are six non-homologous nucleotides at 
positions 121, 207, 283, 291, 304, and 310 (see Figure 2), which result in three amino acid 
variations at residues 41, 102, and 104 (see Figure 3).  The amino acid changes at positions 102 
and 104 occur at the extreme C-terminal end of the amino acid sequence – alterations that would 
likely not significantly affect protein activity.   It is important to note that the change at position 
41, however, occurs in the middle of the putative Nuclear Export Signal sequence.   
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Both PCV-2a VP3 and PCV-2b VP3 are thought to have a Nuclear Export Signal (NES) 
and a Nuclear Localization Signal (NLS), genetic sequences that are responsible for shuttling the 
protein out of the nucleus and back into it, respectively.  Recent experimental findings suggest 
that the NES and NLS for PCV-2a VP3 are functional; however, the same cannot be said 
definitively for PCV-2b VP3 as this has yet to be determined experimentally (19).  The amino 
acid differences between PCV-2a VP3 and PCV-2b VP3 could result in differing cellular 
localization patterns.  This, in turn, could account for the different viral pathogenic relationships 
between these PCV-2 viruses and PMWS.    
Furthermore, PCV-2 VP3 is the established means by which PCV causes viral-induced 
apoptosis (17).  Due to the family relationship and degree of homology, it has been suggested 
that PCV-2 VP3 utilizes a similar apoptotic pathway to that of Chicken Anemia Virus Viral 
Protein 3 (CAV VP3 or Apoptin), though prior to this study, no such findings have supported 
this hypothesis.  Through its mechanism of action, PCV-2 VP3 induces apoptosis in infected 
cells and causes PMWS (4).  Similarly, it is the biochemical action of Apoptin within infected 
chicken cells that induces apoptosis and causes chicken anemia (9).  Possessing a solid 
foundation in the fundamentals of apoptosis is essential for discussing the implications behind 
PCV-2 VP3’s and Apoptin’s shared ability in this area.  
Apoptosis 
Apoptosis, or programmed cell death, is a naturally-occurring process of cellular self-
destruction.   It is a genetically-controlled process that is characterized by distinct morphological 
and biochemical changes within the cell.  Death by apoptosis occurs in two phases: 1) a 
commitment to cell death and 2) the execution of cell death, as observed by archetypal cellular 
alterations (8).  These changes involve the breakdown of the nucleus and a disruption of cell 
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shape and membrane permeability.  More specifically, apoptosis results in chromatin 
condensation, fragmentation of genomic DNA, blebbing of the plasma membrane, cell 
shrinkage, and the creation of small, sub-cellular apoptotic bodies containing cytoplasmic and/or 
nuclear material (5, 6).  In tissues, these apoptotic bodies are engulfed by neighboring cells.  See 
Figure 4 for a schematic depicting these morphological changes. Apoptosis regulates cellular 
homeostasis, tissue development, and the immune system via the elimination of cells that are no 
longer needed.  The apoptotic pathway can also be triggered by external stimuli, leading to cell 
death after DNA damage or viral infection is detected (6).    
It has been speculated that virus-induced apoptosis is a protective host defense 
mechanism, evolved to block the spread of further viral infection by eliminating infected cells 
via an apoptotic pathway before viral replication is complete.  Support for this hypothesis is 
found in viruses that code for genes which specifically inhibit the apoptotic pathway (7).  
However, it seems equally plausible that virus-induced apoptosis contributes to the pathogenesis 
of the disease, ultimately aiding in viral egress.  Indeed, it appears that as a part of their natural 
life cycle, many viruses act to induce apoptosis (4).  Apoptosis may be advantageous to the virus 
because the daughter virions become packaged into the apoptotic bodies which are subsequently 
engulfed by neighboring cells, thus contributing to viral spread (6).  Viruses generally induce 
apoptosis by activating a caspase cascade (4).   
Caspases belong to a family of cysteine proteases and catalyze many steps in the 
apoptotic pathway.  Over a dozen caspases have been identified.  Depending on their place in the 
pathway, each caspase has been grouped into one of two categories: initiators and effectors (4).  
Activation results from caspase-specific cleavage at sites containing aspartic acid.  The initiators 
are synthesized as inactive proenzymes, which form complexes with other proteins.  In response 
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to apoptotic signals, the initiator caspases (those upstream in the pathway, including caspases 2, 
8, 9, and 10) engage in autocatalysis – a process that results in activation.  These activated 
caspases then proceed to activate (via cleavage) the effector caspases (those downstream in the 
pathway, including caspases 3, 6, and 7).  The activated effector caspases go on to cleave other 
target substrates, a process that ultimately results in the morphological and biochemical changes 
characteristic of apoptosis (6, 4).   
 Apoptosis can be initiated via activation of the extrinsic (receptor) pathway or the 
intrinsic (mitochondrial) pathway (24).  (See Figure 5 for a schematic of the extrinsic and 
intrinsic apoptosis pathways.)  The extrinsic pathway is stimulated by the interaction between 
membrane proteins from two different cells.  The extracellular domain of the Fas receptor (also 
known as Apo-1 or CD95) on the apoptosis-inducing cell binds the Fas ligand (FasL) on the 
apoptosis-destined cell.  A cytoplasmic protein known as FADD (Fas Associating Death 
Domain) binds the Fas transmembrane protein and recruits (inactive) procaspase-8.  This 
aggregation results in a conformational change that leads to the assembly of the death-inducing 
signaling complex (DISC).  With procaspase-8 molecules now in close proximity of each other, 
they proceed to cleave and activate each other.  Active caspase-8 is then able to cleave and 
activate procaspase-3 and procaspase-7, forming active effector caspase-3 and active effector 
caspase-7 – the “executioner” caspases responsible for cleaving downstream cellular targets, an 
action that irreversibly commits the cell to apoptosis (24).   
 The intrinsic pathway for apoptosis stems from the mitochondria.  Cytotoxic stimuli and 
proapoptotic signal-transducing molecules, like members of the Bcl-2 protein family, lead to 
increased permeability of the outer mitochondrial membrane.  Bcl-2 activation is triggered by the 
p53 tumor suppressor, though the mechanism by which p53 signals to the Bcl-2 family proteins 
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remains unclear (27). Disruption of the mitochondrial membrane leads to the release of proteins 
from the mitochondrial intermembrane space, including cytochrome c.  The introduction of 
cytochrome c into the cytosol leads to the formation of an apoptosome complex comprised of 
cytochrome c, Apaf-1 (Apoptotic Protease Activating Factor), and procaspase-9.  Upon 
association with the apoptosome, procaspase-9 is cleaved and activated.  Procaspase-3 and 
procaspase-7 are then recruited to the apoptosome, where they are activated by the resident 
caspase-9.  From here, caspase-3 and caspase-7 act as in the extrinsic pathway to cause the 
morphological changes associated with apoptosis (24).  Since caspase-3 and caspase-7 are the 
crucial proteins involved in triggering the cellular and biochemical events of apoptosis, assays 
that measure caspase-3/7 activity (such as Promega’s Apo-ONE® Homogeneous Caspase-3/7 
Assay used in this study) can be used to study the apoptotic ability of proteins such as PCV-2 
VP3 and CAV Apoptin.  
Chicken Anemia Virus (CAV) Apoptin 
Because of its specific apoptotic ability, CAV Apoptin is one of the most intensely 
studied viral proteins. Of particular interest is its known capability to induce apoptosis in 
transformed and malignant cells but not in normal, untransformed cells (9).  Apoptin alone, out 
of context of the rest of the virus, is necessary and sufficient to induce apoptosis and discriminate 
between cancerous and normal cells.  This 14-kDa protein, one of three coded by the simple, 
CAV genome, has been shown to induce apoptosis in nearly every cancerous cell line tested (7). 
Previous studies have demonstrated that Apoptin interacts with the anaphase-promoting 
complex/cyclosome (APC/C), a unit which acts as a major regulator of the cell cycle. Entry of 
Apoptin into the nucleus subsequently inhibits the APC/C by binding to the APC-1 subunit, 
leading to G2/M cell cycle arrest and apoptosis (11). 
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The main goals of Apoptin-based research revolve around two key ideas: determining 
how the protein selectively targets cancer cells and determining the specific biochemical 
mechanism by which it destroys cancer cells.  The study of Apoptin homologs like PCV-2 VP3, 
although in its infancy, merits equal attention since these viral proteins could potentially harbor 
similar cancer-killing capabilities.  Learning more about the action of these viral proteins and the 
basic biochemical differences between primary cells and transformed cells that lend themselves 
to be protected from or susceptible to Apoptin-induced apoptosis is of significant interest to 
cancer researchers; such research has the potential to lead to more effective chemotherapeutic 
agents.  
Apoptin-based research has yielded two interesting insights that have significant 
implications for cancer research.  First, as previously mentioned, Apoptin selectively induces 
apoptosis in transformed cells only.  Expressing Apoptin in primary cells does not seem to 
produce any negative effects (9). Exploring the basis for Apoptin’s cancer-cell selectivity is of 
interest to the research community due to its implications for the creation of more effective 
anticancer therapeutics with minimal adverse side effects.   Similarly, studying whether or not 
PCV-2 VP3 possesses the same ability could also have profound implications for research in this 
field.  
Second, induction of apoptosis in transformed cells occurs in a p53-independent manner. 
The p53 tumor suppressor pathway is a common target for today’s most widely used cancer 
treatments, such as chemotherapy and radiotherapy; thus, such treatments function in a p53-
dependent manner. However, it is important to note that the p53 gene is mutated in about half of 
all human tumors, thereby rendering p53-dependent treatments useless against those cancers.  As 
such, the discovery of novel p53-independent cancer therapies is of significant interest to cancer 
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researchers (6).  To date, the literature suggests that PCV-2 VP3 acts in a p53-dependent manner 
but this study indicates another possibility, implying that PCV-2 VP3 may engage in an 
apoptotic pathway similar to that of Apoptin’s.   
Apoptin’s mechanism of action has been postulated to be dependent on its 
nucleocytoplasmic shuttling activity within an infected cell.  Its localization is directed by an N-
terminal Nuclear Export Signal (NES) and a C-terminal Nuclear Localization Signal (NLS) (12).  
PCV-2a VP3 has been shown to contain a functional NES and NLS (19).  While the functionality 
of an NES or an NLS in PCV-2b VP3 has yet to be confirmed, the high degree of sequence 
homology between PCV-2a VP3 and PCV-2b VP3 and PCV-2b VP3’s apoptosis-inducing 
abilities suggest functional sequences. The transformed cell-specific apoptotic effects of Apoptin 
have been thought to be due to differences in the sub-cellular localization of the protein: in 
primary cells, Apoptin partitions to the cytoplasm, whereas in transformed cells, Apoptin 
partitions to the nucleus (12).  Determining whether PCV-2 VP3 shares this property would be 
cause for a relevant and interesting study.    
Some studies have shown that nuclear localization alone is not sufficient for inducing 
apoptosis in transformed cells, indicating that there is likely another essential factor.  In addition 
to nucleocytoplasmic shuttling, researchers have suggested that multimerization – the 
aggregation of protein molecules – is thought to be a significant aspect in Apoptin’s mechanism 
of action (13).  Multimerization may be essential for the observed sub-cellular localization 
patterns and for the induction of apoptosis.  Apoptin does indeed harbor the ability to form large 
multimers; in vitro, Apoptin spontaneously forms multimers composed of roughly 30 to 40 
subunits (13).  Its multimerization domain, however, overlaps with its NES.   Studies in which 
the NES was mutated in Apoptin resulted in elimination of multimerization, loss of cell-type 
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selectivity, and the ability to induce apoptosis (13). The reduction in aggregate formation from 
the alteration of these N-terminal residues indicates that Apoptin's NES contains essential amino 
acid residues required for multimerization.  To determine the role of multimerization and nuclear 
export activities in cell-type specific apoptosis, these two activities must first be uncoupled.  
Further evidence that multimerization is imperative for Apoptin’s mechanism of action resides in 
the fact that in primary cells Apopotin is heavily multimerized and insoluble, but less 
multimerized and more soluble in transformed cells.  Whether PCV-2 VP3 multimerizes has yet 
to be determined.      
This study of PCV-2 VP3 merits particular attention, specifically to elucidate the reasons 
behind Apoptin’s cell-type selectivity and ability to induce apoptosis in transformed cells, and to 
determine whether it exhibits a similar ability.  It has already been shown that PCV-2 VP3 serves 
a significant function in virus-induced apoptosis, although whether or not it can select for 
transformed cells over primary cells has yet to be shown experimentally (4).   
The Apoptotic Mechanism of PCV-2 VP3 
The apoptotic mechanism of PCV-2 VP3 has been investigated in a few recent studies.  A 
2005 study by the Liu Lab at the National University of Singapore indicated that PCV-2 VP3 
induces apoptosis in cultured porcine kidney (PK15) cells by activating the initiator caspase 8 
pathway (4).  This, in turn, activates the effector caspase-3 pathway.  Two crucial proteins in this 
pathway include CAD (caspase-activated DNase) and ICAD (inhibitor of CAD).  Caspase-3, 
upon activation, cleaves ICAD, which then allows CAD to migrate into the nucleus and degrade 
DNA.  This degradation of genomic DNA leads to the phenotypes characteristic of apoptotic 
cells, and ultimately, cell death (see Figure 6 for a schematic of this apoptotic pathway).  In 
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another study by the same lab, further research suggested that PCV-2 VP3 interacts with a 
porcine p53-induced-RING-H2 (pPirh2) to ultimately cause apoptosis in the infected cells (2). 
 Poly-ubiquitylation of p53 by pPirh2 (an E3 ubiquitin ligase) signals for p53 degradation, 
leading to depressed levels of p53 within the cell.  This action is critical to the health of the cell, 
as homeostasis is maintained through the action of this enzyme.  PCV-2 VP3 binds to pPirh2, 
preventing it from ubiquitylating p53.  Without this chemical signal, p53 is not degraded as fast, 
and thus, the net concentration of p53 increases within the cell.  This increase in p53 
concentration biochemically triggers apoptosis (see Figure 7 for a schematic of this proposed 
apoptotic pathway).  This apoptotic induction occurs through the phosphorylation of a specific 
serine residue at position 146.  Essentially, the phosphorylation of p53 leads to the activation of 
the transcriptional factor p53AIP1 (p53 regulated Apoptosis Inducing Protein 1).  This 
transcriptional factor, in turn, dissipates the mitochondrial membrane potential, an action that 
leads to cell death.    
Another apoptotic pathway instigated by PCV-2 VP3 has also been suggested, one that 
involves the action of two specific kinases: JNK and p38 MAPK (21).  Located at the end of the 
MAPK (Mitogen-Activated Protein Kinase) signal cascade pathway, these kinases phosphorylate 
p53 and other transcription factors.  The activation of these two pathways was found to be 
necessary for PCV-2 replication within the cell.  In addition to phosphorylation, JNK also 
engages in ubiquitylation, including that of p53.  Phosphorylation of JNK, as induced in the 
presence of PCV-2 VP3, prevents the ubiquitylation of p53, therefore preventing its degradation 
within the cell (see Figure 8 for a schematic of this apoptotic pathway).  Furthermore, the 
phosphorylation of p38 (as a result of PCV-2 VP3), contributes to the transcription of two genes 
that are involved in the p53-mediated apoptotic pathway.  From these studies, it appears that 
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PCV-2 VP3 acts in a p53-dependent manner.  However, its homolog Apoptin induces apoptosis 
through a p53-independent pathway.  Although these studies implicate a p53-dependent 
apoptotic pathway, the results of our study demonstrate that PCV-2 VP3, like Apoptin, can also 
act independently of p53.  
  Studying the parallels between PCV-2 VP3 and Apoptin is an exciting area of research. 
Investigation of the key discrepancies between two relatively similar proteins that invoke the 
same outcome – cell death – could lead to more compelling conclusions about differences at the 
nucleotide, amino acid, and molecular levels between the two, and how those result in specific 
biochemical mechanisms within a given cell.  Of particular interest are the effects these viral 
proteins have on transformed cells, since findings could pave the way for novel, more effective 
anticancer therapeutics.  In an effort to explore PCV-2 VP3’s potential for harboring an Apoptin-
like cancer-cell specificity, isolation and cloning of the protein’s NES and NLS was necessary 
for conducting localization experiments.  Furthermore, the killing capacity of PCV-2 VP3 was 
assessed in a p53-null lung carcinoma cell line, and the outcomes of these experiments led to 
revealing conclusions about PCV-2 VP3’s apoptotic pathway in cancerous cells. 
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MATERIALS AND METHODS 
Synthesis and Purification of Insert DNA 
The Nuclear Export Signal (NES) sequence and Nuclear Localization Signal (NLS) 
sequence of both PCV-2a VP3 and PCV-2b VP3 were amplified using the Polymerase Chain 
Reaction (PCR). Several of the primers used for PCR were designed by the Bourque and 
Goldstein MQP team, including the PCV-2a and PCV-2b NES forward primer, the PCV-2a NLS 
forward primer, and the PCV-2a and PCV2b NLS reverse primer.  The PCV-2a and PCV-2b 
NES reverse primer and the PCV-2b NLS forward primer were specially designed for this 
project with an EcoRI site at the 5’ end and a BamHI site at the 3’ end (like the other primers). 
See Table 1 for the primer sequences. 
 
Table 1. PCR Primers for PCV-2a VP3 and PCV-2b VP3 
 
NES forward (PCV-2a 
and PCV-2b) 
5’ CGA ATT CAA TGG TAA CCA TCC CAC CAC TT 3’ 
NES reverse (PCV-2a 
and PCV-2b) 
5’ GCG GAT CCT CAG TCA GAA ATT TCC GCG GGC 3’ 
 NLS forward (PCV-2a) 5’ GCG AAT TCA AAA CGT TAC AGG GTG CT 3’ 
 NLS forward (PCV-2b) 5’ GCG AAT TCA AAA CGT TAC AGG GTA CTG CTC 3’ 
NLS reverse (PCV-2a 
and PCV-2b) 
5’ GCG GAT CCA ATT ACT TAT TGA ATG TG 3’ 
  
 
A 100-fold dilution of PCV-2a VP3 in Green Fluorescent Protein (GFP) vector and of 
PCV-2b VP3 in GFP vector was prepared.  Four PCR reactions were set up in parallel on ice.  
Each reaction tube contained the following: 1 µL Taq DNA polymerase, 1 µL template DNA, 1 
µL forward primer, 1 µL reverse primer, 1 µL dNTP mix, 2 µL 10x PCR buffer solution, and 13 
µL ddH2O. The protocol program was set to the following parameters: 1)  94oC for 2 min., 2)  
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95oC for 30 sec, 3) 55oC for 30 sec., 4) 72oC for 30 sec., 5.) goto step 2 for 25 cycles, 6.) 72oC 
for 4 min, 7.) 10 oC.   
The PCR products were isolated using a 0.9% agarose gel prepared with 1X Tris-Acetate-
EDTA (1 M acetate and 0.05 M EDTA) with 5 µL of ethidium bromide for DNA staining.  Four 
eppendorf tubes, one for each PCR product, were prepared with the following contents: 6 µL 
PCR product, 2 µL of ddH2O, and 2 µL of 5X loading dye (30% glycerol, 0.25% bromophenol 
blue, 69.75% ddH2O).  Each sample (total of 10 µL) was loaded onto the gel. The gel was run 
initially at 50 volts until the samples had completely exited the wells, at which time the voltage 
was turned up to 90 volts until the dye had traveled approximately halfway down the length of 
the gel.  
Once the gel had run, the products were viewed using a UV lamp and excised from the 
gel using a razor blade.  The bNES DNA gel slice (0.05 g) and the bNLS gel slice (0.10 g) were 
purified using MP Biomedicals GENECLEAN® Kit. Three volumes of NaI (300 µL NaI for 
each 0.1 g of gel) were added to the gel slices. They were incubated at 55oC for 10 min. to melt 
the agarose. 10 µL of glassmilk was added to each, mixed gently, and incubated for 5 min. The 
glassmilk was pelleted by centrifugation and the supernatants discarded. For a total of three 
times, the pellets were washed and re-suspended in 500 µL of New Wash Solution, then 
centrifuged to pellet again. The pellets were allowed to air dry at room temperature.  30 µL of 
pre-warmed 1X Tris-EDTA (TE) was added to each tube.  The pellets were resuspended again, 
then pulsed on the centrifuge for 2 minutes. The resultant supernatant was transferred to new 
eppendorf tubes and stored at -20 oC.    
The aNES and aNLS DNA were purified from the agarose using Promega’s Wizard® 
PCR Preps DNA Purification System. 1 mL of resin was added to each gel slice in an eppendorf 
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tube and incubated at 65oC for 5 min. to melt the gel. The entire resin/DNA mixtures were 
transferred to syringe barrels and pushed through the Wizard® Minicolumns. 2 mL of 80% 
isopropanol was added to the syringes and pushed through to wash the columns.  The 
minicolumns were then each transferred to a new eppendorf tubes and centrifuged for 20 sec. at 
12,000 x g. The minicolumns were transferred to another set of new tubes and 50 µL of warmed 
ddH2O was added to each. After waiting for 1 min, the tubes were centrifuged for 20 sec at 
12,000 x g to elute the DNA.  
Cloning Into T-Vector 
The Promega pGEM T-Vector system kit was used to clone the purified PCR produces 
(aNES, aNLS, bNES, and bNLS) into T-Vector. The standard reactions contained 5 µL of 2X 
ligation buffer, 1µL of T-Vector, 3 µL of PCR product, and 1 µL of T4 DNA Ligase. The 
positive control reaction contained 5 µL of 2X ligation buffer, 1 µL of T-Vector, 2 µL of control 
insert DNA, 1 µL of T4 DNA ligase, and 1 µL of ddH2O.  The negative control reaction 
contained 5 µL of 2X ligation buffer, 1 µL of T-Vector, 1 µL of T4 DNA ligase, and 3 µL of 
ddH2O.  All reactions were prepared on ice.  
After mixing each reaction, they were incubated at room temperature for 1 hr. After the 
incubation period, the reactions were mixed with 50 µL of DH5α e.coli cells. After mixing (via 
flicking the tube), the tubes were incubated on ice for 20 min.  Then they were heat shocked in a 
42o C water bath for 60 sec. and immediately returned to ice for another 2 min. 450 µL of LB 
recovery media was added to each tube, which were then incubated at 37oC with rotation for 1 
hr. All the reactions were plated on LB-AMP/IPTG/X-gal plates and incubated at 37oC 
overnight. Only the white colonies were selected as they were the only colonies with insert.  
These white colonies were inoculated in 3 mL of AMP LB media and shaken at 37oC overnight.  
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A plasmid prep was performed on each of the overnight cultures. 1.5 mL of each culture 
was transferred to eppendorf tubes and centrifuged at 3,000 x g for 5 min. The supernatant was 
discarded and 1.5 mL of each culture was added to the appropriate tube and centrifuged at 2000 
x g for 5 min. Each pellet was re-suspended by vortexing in 100 µL MPS I solution. MPS II 
solution was prepared made fresh with 100 µL 10 N NaOH, 500 µL 10% SDS, and H2O for a 
total volume of 5 mL. 200µL of MPS II solution was added to each tube and gently mixed. The 
cells incubated on the bench for 3 min. to ensure complete cell lysis and 150 µL of MPS III was 
added and mixed by vortexing at low speed. The reactions were incubated in ice for 10 min. and 
then centrifuged at 12,000 x g for 5 min. to pellet the unwanted cellular contents. The 
supernatants were recovered and 2 volumes (~900 µL) of cold 100% ethanol was added to each 
and vortexed to mix.  The tubes were incubated on ice for 2 min. and centrifuged for 5 min at 
12,000 x g to pellet the precipitated DNA. The supernatants were discarded.  The pellets were 
rinsed with 1 mL 70% ethanol (no re-suspension) and then centrifuged again for 2 min. at 12,000 
x g.   After removing as much residual ethanol as possible, the pellets air-dried and were re-
suspended in 50 µL of 1X TE. 
Both constructs were verified via a restriction digest.  The restriction digests reactions 
were set up as follows: 3 µL DNA, 1 µL RNAse A, 1 µL EcoRI, 1 µL BamHI, 2 µL Buffer E, 
and 12 µL ddH2O.  Three controls were also run using the same components with the following 
exceptions – one contained no enzymes, one containing only one of the enzymes (EcoRI), and 
the third contained the other enzyme (BamHI).  These restriction digests were incubated at 37˚C 
for 2 hours.  They were then run on a 0.9% agarose gel as previously described and upon 
completion, the gel was viewed with a UV lamp to confirm the presence of insert.  
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With construct verification, midipreps were prepared for each using the Promega Wizard 
Plus Midipreps DNA Purifications System. 10 µL of each of the T-vector constructs (bNES in T-
vector and bNLS in T-vector) were added to 50 µL of DH5α e.coli cells.  They were incubated 
on ice for 20 min. and then heat-shocked at 42oC for 50 sec. The cells were returned to ice once 
again for 2 min. and 450 µL of LB recovery media was added to them. The tubes were incubated 
at 37oC with rotation for 1 hr. After the incubation period, 50 µL of the cells were added to 100 
mL of media with 100 µL of ampicillin and incubated at 37oC with shaking overnight.  
100 mL of cells in each tube were pelleted at 10,000 x g for 10 min. at 4oC. The 
supernatants were removed and the pellets were re-suspended in 3 mL of Cell Resuspension 
Solution. 3 mL of Cell Lysis Solution was added to each tube and inverted to mix.  Next, 3 mL 
of Neutralization Solution was added and tubes were again inverted to mix.  The tubes were 
centrifuged at 14,000 x g for 15 min. at 4oC and the supernatant containing DNA was recovered 
and transferred to new tubes. Purification Resin (10 mL) was added to each tube and mixed by 
swirling. Using the Midicolumn and vacuum, the DNA/Resin mixture was pushed through the 
column. 15 mL of Column Wash Solution with ethanol was also pushed through the column two 
separate times and the pellet was allowed to vacuum dry for 30 sec. after all the liquid had left 
the column. The column was then removed, placed in an eppendorf tube, and then centrifuged 
for 2 min. at 10,000 x g. The column was placed in a new eppendorf tube and 300 µL of pre-
warmed (~70oC) ddH2O was added and allowed to sit for 1 min. After, the tubes were 
centrifuged for 20 sec. at 10,000 x g to elute the DNA.  The Midicolumns were then discarded 
and the eppendorf tubes were centrifuged again, this time at 10,000 x g for 5 min. to pellet the 
resin. The supernatants were collected and transferred to new tubes.  The DNA was stored at -
20˚C.  Aliquots of each T-vector construct were sent out for sequencing.  
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Midiprep of PCV-2a VP3 in GFP Vector 
Due to a low initial concentration, the PCV-2a VP3 in GFP Vector stock solution was 
midiprepped to increase its concentration.  This was achieved using Promega’s Midiprep Kit. 10 
µL of the stock DNA was first added to 50 µL of DH5α e.coli cells. They were incubated on ice 
for 20 min. and then heat-shocked at 42oC for 50 sec. The cells were returned to ice once again 
for 2 min. and 450 µL of LB recovery media was added to them. The tubes were incubated at 
37oC with rotation for 1 hr. After the incubation period, 50 µL of the cells were added to 100 mL 
of media with 100 µL of kanamycin and incubated at 37oC with shaking overnight.  The rest of 
the midiprep procedure was identical to that of the T-vector constructs as described in the 
previous section. 
Transfection of H1299 Cells 
Using the previously engineered PCV-2a VP3 and PCV-2b VP3/GFP constructs, H1299 
lung cell carcinoma cells were transfected using the Qiagen Effectene Transfection protocol.  A 
third set of wells were transfected with Apoptin (the positive control) and a fourth set of wells 
were carried through the transfection process with no DNA (the negative control).  Each 
transfection was performed in triplicate.  
The transfected H1299 cells were incubated under normal growth conditions of 37˚C and 
5% CO2.  The media used was Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal 
bovine serum (FBS) and the antibiotic formulation PSF (penicillin, streptomycin, and 
fungizone).  200 µL of the H1299 cells were passed into 96-well plate and were approximately 
70% confluent.  Both PCV-2a and 2b constructs were dissolved in TE buffer with Buffer EC.  
2.4 µL of Enhancer was added and the mixture was vortexed. These were incubated at 25˚C for 5 
min. and centrifuged. The growth media was aspirated from the plate and the cells were washed 
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with 200 µL of PBS. 100 µL of fresh media were added to the cells. 50 µL of the transfected 
complexes were added onto the cells in a drop-wise manner and incubated under normal growth 
conditions for 24 hours. 
Apoptosis Assay 
The Apo-ONE® Homogenous Caspase-3/7 Assay from Promega was used for the 
detection of caspase-3 and caspase-7 activity. The reactions were run in triplicate with three 
positive controls (cells transfected with Apoptin), three negative controls (“no DNA” controls), 
three PCV-2a VP3 samples, and three PCV-2b VP3 samples.  After the 24-hour transfection 
period, the cells were washed with Phosphate Buffered Saline (PBS) and 50 µL of fresh media 
was added to each well.  To conduct the assay, 50 µL of Apo-ONE Caspase-3/7 Reagent was 
added to each well.  The contents of the wells were mixed and incubated at room temperature 
overnight.  After a period of 18 hours, the fluorescence emitted from each well was measured 
using a fluorescence spectrometer with an excitation wavelength of 499 nm and a maximum 
emission wavelength of 521nm. 
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RESULTS 
High Degree of Homology between PCV-2a VP3 and PCV-2b VP3  
To determine the homology between PCV-2a VP3 and PCV-2b VP3, both the nucleotide 
and the amino acid sequences were aligned and analyzed using CLC Main Workbench.  The 
nucleotide alignment (see Figure 2) indicated a 98% similarity between the two genes, with 
alterations occurring at nucleotides 121, 207, 283, 291, 304, and 310.  These six nucleotide 
variations result in three amino acid differences in the proteins, located at positions 41, 102, and 
104 (see Figure 3).  At position 41, PCV-2a VP3 contains a glycine residue (non-polar) whereas 
PCV-2b VP3 contains a serine residue (polar, uncharged); at position 102, PCV-2a contains a 
phenylalanine residue (non-polar, aromatic) whereas PCV-2b contains a leucine residue (also 
non-polar); at position 104, PCV-2a contains a lysine residue (polar, charged) whereas PCV-2b 
contains a glutamine residue (polar, uncharged).   
 Nucleotide alignments with CAV Apoptin indicate that PCV-2a VP3 and PCV-2b VP3 
contain a Nuclear Export Signal (NES) sequence and a Nuclear Localization Signal (NLS) 
sequence (20).  The amino acid difference between PCV-2a VP3 and PCV-2b VP3 at position 41 
occurs in the middle of the putative NES (and does not represent a functional substitution).  The 
amino acid differences at positions 102 and 104 possibly occur at the very end of the NLS, or 
directly after (and do represent functional substitutions).   
To investigate the functionality of these sequences, they must first be separated from each 
other for use in future localization experiments.  To that end, primers were designed to flank 
each sequence so that the desired DNA segments (the NES and the NLS) could be selectively 
amplified using the Polymerase Chain Reaction (PCR).  
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Formation of Truncation Mutants  
Using specifically-designed primers and PCR, the Nuclear Export Signal (NES) and 
Nuclear Localization Signal (NLS) of PCV-2a VP3 and PCV-2b VP3 were isolated.  For the 
NES, only one set of primers (forward and reverse) were needed, as the nucleotide sequences for 
PCV-2a VP3 and PCV-2b VP3 were identical in this region of their genomes.  However, for the 
NLS, PCV-2a VP3 and PCV-2b VP3 each required slightly different forward primers (and they 
shared the same reverse primer).  Three out of the five primers needed to run this PCR procedure 
were previously ordered and available for use from the Bourque and Goldstein MQP team.  The 
other two – the PCV-2a/PCV-2b NES reverse primer and the PCV-2b NLS forward primer – 
were designed for this project.   
All of the primers were specially engineered with an EcoRI restriction site (GAATTC) at 
the 5’ end and a BamHI restriction site (GGATCC) at the 3’ end, which would, in turn, confer 
these restriction sites to the truncation mutants, allowing them to be cloned into pGEM T-vector 
(henceforth referred to as simply “T-vector”) and eventually, Green Fluorescent Protein (GFP) 
vector.  The four PCR products (aNES, aNLS, bNES, and bNLS) were successfully isolated on 
an agarose gel, as shown in Figure 9.  From this gel, it is possible to see that the NLS is a slightly 
smaller segment of DNA than the NES.   These bands were excised from the gel and purified so 
that the sequences could be cloned into T-vector.  
Cloning of Truncation Mutants (PCV-2b VP3 NES and NLS) into pGEM T-Vector 
 The truncation mutants (PCV-2b NES and PCV-2b NLS) obtained from PCR needed to 
first be cloned into T-vector before the target vector (GFP vector).  This step allows for the 
stabilization of the PCR products and for easy amplification of the sequences.  (See Figure 10 for 
a schematic of the steps needed to reach the target constructs.)  The ligations of the bNES and 
28 
 
bNLS sequences into T-vector were successfully completed in this study.  Future work will 
involve excising these sequences out of T-vector and ligating them into GFP vector.  These GFP 
constructs can then be used in sub-cellular localization experiments. 
To mass produce the T-vector/truncation mutant constructs, competent E.coli were 
transformed with this DNA and allowed to replicate in vivo.  From there, the plasmid DNA 
constructs were isolated from the bacterial cells.  To confirm the presence of insert (the 
truncation mutant) in T-vector, a restriction digest of the plasmids were performed and the DNA 
was visualized on an agarose gel.  
The restriction profile was created using the restriction enzymes EcoRI and BamHI.  The 
uncut construct served as a control (see Lane 1 of Figure 11a and 11b) and the double digest of 
the vector yielded an affirmative result (see Lane 2 of Figure 11a and 11b).  The uncut plasmid 
resulted in a standard plasmid banding pattern on the gel: two bands – the higher one 
representing nicked plasmid and the lower one representing supercoiled plasmid.  The banding 
pattern of the cut plasmid in both Figure 11a and 11b indicates that both the NES and NLS were 
successfully cloned into T-vector, as seen by the dropout inserts.  The brighter band located 
above the dropout inserts on the gel represents linearized T-vector.  Since the EcoRI and BamHI 
sites uniquely flank the NES and the NLS inserts, it is evident that the T-vector constructs were 
engineered correctly.   
Once the T-vector constructs were confirmed, a Midiprep was performed on them to 
concentrate the DNA.  A UV-Vis spectrometer was used to determine the concentration of DNA 
in each Midiprep.  The bNES in T-vector Midiprep was determined to be 0.2078 µg/µL 
(absorbance at 260 nm was 0.0042) and the bNLS in T-vector Midiprep was determined to be 
1.5690 µg/µL (absorbance at 260 nm was 0.0314).  Samples of each at ~0.2 µg/µL were sent to 
29 
 
Macrogen USA for sequencing.  This data was needed to check for possible mutations in the 
NES and NLS sequences.   
Confirmation of pGEM T-Vector Constructs via Sequence Analysis 
 To further confirm the presence of the PCV-2b VP3 NES and NLS inserts in T-vector, 
nucleotide and amino acid alignments were created using CLC Main Workbench.  The T-vector 
nucleotide sequences containing bNES and bNLS obtained from Macrogen USA were compared 
to both full and truncated versions of PCV-2b VP3’s nucleotide sequence obtained from 
PubMed.   
 Figures 12 and 13 show the nucleotide alignment between the PCV-2b VP3 PubMed 
sequence and the bNES T-vector insert sequence.  An analysis of the two sequences indicates 
that there is one nucleotide change.  This occurs at position 89 – there is a cytosine in the 
PubMed sequence and a thymine in the T-vector bNES sequence.  This change was likely due to 
a Taq-induced mutation. An amino acid alignment (see Figures 14 and 15) indicated that the one 
nucleotide modification resulted in one amino acid conversion between the two protein 
sequences.  This difference occurs at position 30.  There is a threonine residue in the PubMed 
sequence and an isoleucine residue in the T-vector bNES sequence.   This is a non-functional 
substitution, but it occurs prior to the putative export signal.   
 Figures 16 and 17 show the nucleotide alignment between the PCV-2b VP3 PubMed 
sequence and the bNLS T-vector insert sequence. An analysis of the two sequences indicated 
that there are two nucleotides which vary.  These occur at positions 304 and 310 in Figure 16 and 
at 111 and 117 in Figure 17.  At the first position, there is a cytosine in the PubMed sequence 
and a thymine in the T-vector bNLS sequence.  At the second position, there is a cytosine in the 
PubMed sequence and an adenine in the T-vector bNLS sequence.  An amino acid alignment 
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(see Figures 18 and 19) indicated that these two nucleotide mutations resulted in two amino acid 
differences between the two protein sequences.  These conversions occur at positions 102 and 
104 in Figure 18 and at positions 38 and 40 in Figure 19.  At the first position, there is a leucine 
residue in the PubMed sequence and a phenylalanine residue in the T-vector bNLS sequence.  At 
the second position, there is a glutamine residue in the PubMed sequence and a lysine residue in 
the T-vector bNLS sequence.  These changes indicate that the PCV-2a VP3 NLS was created and 
inserted into T-vector, instead of PCV-2b VP3 NLS.  However, both of these amino acid 
variations occur at the very end of the sequence and may not be required for functional NLS 
activity.  In parallel with conducting these ongoing molecular cloning initiatives, the cancer-
killing capacity of both PCV-2a VP3 and PCV-2b VP3 was investigated.    
PCV-2b VP3 Induces Apoptosis in Cancerous Cells via a p53-Independent Pathway  
 To assess the ability of PCV-2a VP3 and PCV-2b VP3 to induce apoptosis in transformed 
cells, constructs of each viral protein in GFP vector were transfected into H1299 cells – a non-
small cell lung carcinoma cell line that lacks p53.  After a transfection period of 24 hours, 
Promega’s Apo-ONE ® Homogeneous Caspase-3/7 Assay was used to detect caspase-3/7 
activity.  Figure 20 depicts how the assay works.   Essentially, the assay requires the addition of 
a special substrate, Z-DEVD-R110.  In apoptotic cells, effector caspases such as caspase-3 and 
caspase-7 will be activated by initiator caspases.  These caspases will go on to cleave other 
targets, such as the Z-DEVD-R110 substrate from the kit.  Upon cleavage of the DEVD peptides 
from Z-DEVD-R110, the leaving group Rhodamine 110 is produced.  Rhodamine 110 is an 
intensely fluorescent compound with an excitation wavelength of 499 nm and an emission 
wavelength of 521 nm.  Since the fluorescence is a result of caspase activity, it can be used as a 
means of detecting apoptosis activity as well.  
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After a period of 18 hours, fluorescence from wells containing lysed, transfected cells 
was detected with a fluorescence spectrometer and the output was graphed.  This data resulted in 
two sets of distinct curves that clustered together.  As shown by the fluorescence curves that 
peak at 521 nm in Figure 21, Apoptin and PCV-2b VP3 successfully induced apoptosis in the 
p53-null H1299 cells.  PCV-2a VP3 along with the ‘no DNA’ negative control exhibited no such 
fluorescence emission, and thus, apoptotic behavior.   These novel results raise interesting 
questions about the cancer-killing abilities of the PCV-2 isoforms and direct the course of future 
study for these Apoptin homologs.  
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DISCUSSION 
 Porcine Circovirus Type 2 Viral Protein 3 (PCV-2 VP3) is a homolog of the cancer-
killing protein Apoptin from the Chicken Anemia Virus.  Studies of Viral Protein 3 from PCV-
2’s highly similar isoforms – PCV-2a and PCV-2b – could potentially illuminate the basis for 
Apoptin’s cancer cell selectivity and killing capacity.  Furthermore, these kinds of studies could 
lead to more effective cancer treatments that operate via a similar mechanism within the cell.  In 
this study, preliminary strides were taken to analyze the cellular localization patterns exhibited 
by PCV-2 VP3, and the cancer-killing ability of PCV-2 VP3 was assessed in a non-small cell 
lung carcinoma cell line that lacked the p53 tumor suppressor. As many human cancers lack the 
p53 tumor suppressor, the discovery of p53-independent apoptotic pathways that lead to cancer 
cell destruction is of utmost importance for the development of new anticancer therapeutics.   
A sequence alignment of PCV-2a VP3 and PCV-2b VP3 was performed to explore their 
level of homology. The virus proteins were 98% homologous at the nucleotide level, differing at 
positions 121, 207, 283, 291, 304, and 310 and resulting in a change of three amino acids at 
positions 41, 102, and 104 (Figures 2 and 3). These changes, albeit minor, could be a major 
cause for differences in viral pathogenicity between PCV-2a and PCV-2b.  
The apoptosis assay yielded an interesting result: PCV-2a VP3 did not induce apoptosis 
in the H1299 lung carcinoma cell line, but PCV-2b VP3 did quite vigorously.  PCV-2b VP3 
induced apoptosis in the cancer cells as much as the positive control (wild-type Apoptin), 
whereas PCV-2a VP3 performed on par with the negative (‘no DNA’) control, failing to induce 
apoptosis in the transformed cell line.   
Although the resultant fluorescence curves shown in Figure 21 cluster nicely together in 
general, there are noticeable variations in the degree of fluorescence observed, even between 
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samples that occurred in triplicate.  This variation is likely due to variability in cell plating 
between wells and/or differences in transfection efficiencies.  Overall, however, this data is 
viable and from it can be drawn two thought-provoking conclusions: 1) PCV-2b VP3, like 
Apoptin, induces apoptosis in cancerous cells via a p53-independent pathway and 2) PCV-2a 
VP3 and PCV-2b VP3 have drastically different apoptotic abilities, despite being 98% 
homologous at the nucleotide level.   
All previous studies have indicated that PCV-2 VP3 induces apoptosis via a p53-
dependent pathway.  This study demonstrates for the first time that PCV-2b VP3 can induce 
apoptosis via a p53-independent pathway, as the transformed cell line used in this study lacks the 
p53 tumor suppressor.   This result does not necessary negate past studies; instead, it 
compliments those studies, suggesting that PCV-2b VP3 is capable of also engaging an apoptotic 
pathway that does not require the presence of p53.  The biochemical details of that pathway have 
yet to be determined.   However, this discovery brings up several interesting questions, one of 
which is the following: Does PCV-2b VP3 induce apoptosis via the same basic mechanism as 
Apoptin?  Further evidence that PCV-2b VP3 might engage in a similar pathway is indicated in 
the literature.   
Studies have suggested that PCV-2b VP3, like Apoptin, targets an E3 ubiquitin ligase to 
initiate the biochemical activities that ultimately lead to programmed cell death.  PCV-2b VP3 
has been shown to interact with the E3 ubiquitin ligase pPirh2, whereas Apoptin has been shown 
to interact with the anaphase-promoting complex, also an E3 ubiquitin ligase (2, 6).  To further 
investigate the interaction between PCV-2b VP3 and these apoptotic targets, a yeast two-hybrid 
system can be used. This system utilizes physical protein-protein interactions to change a cell 
phenotype. Cells which die or exhibit a change in phenotype can be screened and selected, and in 
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this specific case, demonstrate the interaction between PCV-2b VP3 or Apoptin and specific 
apoptotic targets, implicating a possible mechanistic pathway.   
Apoptin is known to shuttle out and into the nucleus due to its NES and NLS sequences, 
a characteristic which is thought to be linked to its cancer-killing capacity.  In primary cells, 
Apoptin partitions to the cytoplasm and does not induce apoptosis but in transformed cells, 
Apoptin separates to the nucleus and does induce apoptosis.  Therefore, another question that is 
raised when considering the parallels between Apoptin’s mechanism of action and PCV-2b 
VP3’s mechanism of action is the following: does PCV-2b VP3’s apoptotic activity depend on 
nucleocytoplasmic shuttling and its resultant localization patterns within a given cell?  If so, does 
its sub-cellular localization patterns allow it to selectively target and destroy transformed cells, 
leaving primary cells unharmed?  Determining whether or not PCV-2b VP3 functions in a 
similar manner could lead to conclusions about both Apoptin’s and PCV-2b VP3’s apoptotic 
mechanism.  Using the PCV-2b NES/NLS constructs created in this study to move forward with 
cellular localization experiments would shed light on these questions and direct the course of 
action for future research in this area.   
In order to analyze PCV-2b VP3 localization, the Nuclear Export Signal (NES) sequence 
and Nuclear Localization Signal (NLS) sequence were isolated from each other and 
reconstructed into new vectors (T-vector).  However, the terminal vector for these genetic 
sequences is Green Fluorescent Protein (GFP) vector.  The expression of these constructs will 
yield two fusion proteins – one with the NES attached to GFP and the other with the NLS 
attached to GFP.  Once transfected into cells, these fusion proteins can be tracked using 
fluorescence microscopy as a result of GFP’s emission of green light.   
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Before these GFP constructs can be made, however, the NES and NLS had to be cloned 
into T-vector, as was accomplished in this study.  From here, a restriction digest on these T-
vector clones using EcoRI and Bam HI to re-isolate the truncation mutants following by a 
subsequent ligation with linearized GFP vector will yield the target vectors for the desired 
localization experiments (see Figure 10 for a schematic of these molecular cloning steps to yield 
the final constructs needed for the future localization experiments).    
To verify that the NES and NLS sequences were conserved after the PCR and molecular 
cloning processes, the T-vector constructs were sequenced by Macrogen USA and compared to 
the accepted PubMed sequence found in the online database.  Analysis of the PCV-2b NES 
sequences indicated that the entire sequence was conserved except for one nucleotide change 
(position 89 in Figures 12 and 13).  This point mutation generated a change in amino acid for the 
sequence, a substitution of an isoleucine for a threonine.  Neither of these amino acids are 
charged; however, threonine is polar due to its hydroxyl group but isoleucine is not.  Although 
this is not a functional substitution, this mutation occurs before the putative export signal begins.   
 An analysis of the PCV-2b VP3 NLS sequences indicated that there are two nucleotides 
which vary.  At the first position, there is a cytosine in the PubMed sequence and a thymine in 
the T-vector bNLS sequence.  At the second position, there is a cytosine in the PubMed sequence 
and an adenine in the T-vector bNLS sequence.  These nucleotide differences translated into two 
amino acid differences between the two proteins.  At the first position, there is a leucine residue 
in the PubMed sequence and a phenylalanine residue in the T-vector bNLS sequence.  At the 
second position, there is a glutamine residue in the PubMed sequence and a lysine residue in the 
T-vector bNLS sequence.  These changes indicate that the PCV-2a VP3 NLS was created and 
inserted into T-vector, instead of PCV-2b VP3 NLS.  However, both of these amino acid 
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variations occur at the very end of the sequence and may not even be required for functional 
NLS activity.   
Once the NES and NLS sequences are cloned into GFP vector, further studies can be 
conducted to determine whether or not they are functional.  Comparing the localization patterns 
of PCV-2a VP3 and PCV-2b VP3 would also highlight the potential differences the few amino 
acid changes between the two might have, if any, on subcellular localization, and thus, on 
virulence and apoptotic ability.     
 The sharp contrast between PCV-2a VP3’s apoptotic ability and PCV-2b VP3’s apoptotic 
ability was stunning.  PCV-2 VP3 has already been linked to the induction of apoptosis, and it is 
known that the PCV-2b VP3 isoform causes a much more severe case of PMWS in pigs. The two 
proteins only vary by three amino acid residues with two of the permutations located at the very 
ends of the proteins (see Figure 3).  Incidentally, these small changes made the difference 
between being able to kill cancer cells and not being able to kill cancer cells.  Determining which 
amino acid(s) are primarily responsible for this differing cancer-killing capacity could yield 
informative insights into the apoptotic mechanism at work.  Furthermore, now that PCV-2b VP3 
has been implicated with apoptotic abilities in a p53-null cancer cell line, it would be pertinent to 
also study its apoptotic ability in primary cell lines to determine whether or not PCV-2b VP3 
possesses the Apoptin-like ability of selectively inducing apoptosis in transformed cells only.   
One way in which to determine which of the three amino acid(s) are responsible for the 
difference in apoptotic ability between PCV-2a VP3 and PCV-2b VP3 is to create reversion 
mutants.  This would involve mutating PCV-2a VP3 one amino acid at a time to resemble PCV-
2b.  With each reversion mutant, the same apoptosis assay performed in this study should be 
repeated to observe whether or not that particular mutation had an effect on the protein’s ability 
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to induce apoptosis in the H1299 cell line.  A reversion mutant of all three amino acids in PCV-
2a VP3 to convert it completely to PCV-2b VP3 will serve as the positive control, as it should 
act in the same way as the PCV-2b VP3 used in this study.   In this way, it will be possible to 
determine exactly which amino acid(s) is/are responsible for the differences in activity (and 
pathogenesis) between the two, and further studies might be able to determine why that is the 
case.  For example, the amino acid change located in the middle of the protein occurs in the 
NES.   It is possible that if the NES has a significant function in the mechanism, that one change 
could have altered NES activity for PCV-2a VP3.  A 2009 study, however, indicates that PCV-2a 
VP3 does indeed contain a functional NES (19).  This result implies that there is likely another 
element involved. 
In addition to sub-cellular localization, multimerization is thought to be essential for 
Apoptin’s cancer-killing ability (13).  It is also known that the NES domain overlaps with the 
multimerization domain, and efforts have been made to uncouple the two activities to better 
understand each one’s role in viral-induced apoptosis (28).  Therefore, if multimerization is 
indeed a necessary characteristic of PCV-2b VP3 that allows it to induce apoptosis in 
transformed cells, it is possible that the one amino acid change between PCV-2a VP3 and PCV-
2b VP3 that is located within the putative NES could have affected the multimerization ability of 
each, leading to the observed differences in cancer-killing ability. Using a yeast two-hybrid assay 
to assess the multimerization ability of PCV-2a VP3 and PCV-2b VP3 would shed light on this 
issue.   
 The study of PCV-2 VP3’s apoptotic potential in parallel with that of Apoptin’s could 
illuminate our understanding of cancer-cell selectivity tactics and killing mechanisms that might 
lead to new, more effective anticancer therapeutics for a broad range of cancers.  Who would 
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have guessed that the simplest eukaryotic viruses have harbored the ability to not only 
differentiate between cancerous and healthy cells, but induce cell death in the former while 
maintaining the integrity of the latter.  Discoveries in this area, therefore, have profound 
implications for cancer research.   
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FIGURES 
 
 
 
 
 
Figure 1. The PCV Genome.  The PCV genome contains three open reading frames.  The first 
codes for the viral replication proteins, the second codes for the capsid protein, and the third 
codes for an Apoptin homolog that is currently being investigated for its cancer killing ability. 
 
 
40 
 
 
 
Figure 2. PCV-2a VP3 and PCV-2b VP3 Nucleotide Alignment.  At the nucleotide level, 
PCV-2a VP3 and PCV-2b exhibit a 98% homology, with differences occurring at nucleotides 
121, 207, 283, 291, 304, and 310. 
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Figure 3. PCV-2a VP3 and PCV-2b VP3 Amino Acid Alignment.  At the amino acid level, 
PCV-2a VP3 and PCV-2b only differ by three amino acids.  These differences occur at positions 
41, 102, and 104 (indicated in red). 
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Figure 4. Morphology Changes That Occur During Apoptosis.  When a cell commits to 
apoptosis, it shrinks and its chromatin condenses.  The cellular membrane blebs and nucleus 
undergoes fragmentation.  Eventually, the cell forms many small “apoptotic bodies” that are 
eventually phagocytosed by the surrounding cells. 
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Figure 5. The Extrinsic and Intrinsic Apoptotic Pathways.  The extrinsic pathway is triggered 
by external cellular stimuli that results in the binding of the Fas ligand to the Fas receptor.  The 
cytoplasmic protein known as FADD (Fas Associated Death Domain) binds the Fas 
transmembrane protein and recruits procaspase-8.  Together, this complex is called DISC (Death 
Inducing Signaling Complex).  The proscaspase-8 molecules cleave and activate each other, and 
active caspase-8 is able to cleave and activate procaspase-3 and procaspase-7 to form active 
caspase-3 and active caspase-7.  The intrinsic pathway is induced by proapoptotic signal-
transducing molecules, like Bcl-2, that increase the permeability of the mitochondrial membrane.  
This allows for the release of cytochrome c from the mitochondrial intermembrane space, 
allowing it to complex with Apaf-1 (Apoptotic Protease Activating Factor) and procaspase-9 
(forming the “apoptosome”).  Procaspase-9 is immediately cleaved and activated, and proceeds 
to cleave and activate procaspase-3 and procaspase-7.  Caspase-3 and caspase-7 are responsible 
for cleaving downstream cellular targets, an action that irreversibly commits the cell to 
apoptosis. 
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Figure 6. The Caspase-8-mediated Apoptotic Pathway.  Once procaspase-8 is cleaved and 
activated, it activates procaspase-3.  Activated caspase-3 cleaves ICAD (inhibitor of CAD), 
freeing CAD (caspase-activated DNase) and allowing it to migrate to the nucleus.  Once in the 
nucleus, CAD degrades the DNA.  Degradation of genomic DNA leads to the phenotypes 
characteristic of apoptotic cells, and ultimately, cell death. 
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Figure 7. The pPirh2/p53-mediated Apoptotic Pathway.  Poly-ubiquitylation of p53 by 
pPirh2 (an E3 ubiquitin ligase) signals its degradation, leading to depressed levels of p53 within 
the cell.  This action is important to the health of the cell, as homeostasis is maintained through 
the action of this enzyme. It has been suggested that in PCV-2 VP3-infected cells, PCV-2 VP3 
binds to pPirh2, preventing it from ubiquitylating p53. Without this chemical signal, p53 
accumulates within the cell, ultimately leading to apoptosis. 
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Figure 8. The JNK/p53-mediated Apoptotic Pathway.  It has been suggested that PCV-2 VP3 
induces the phosphorylation of JNK which, in turn, prevents the ubiquitylation of p53.  Without 
this chemical signal, p53 accumulates within the cell, ultimately leading to apoptosis. 
 
 
 
 
47 
 
 
 
 
 
 
 
 
Figure 9. PCR Products Isolated on a 0.9% Agarose Gel.   PCV-2a NES, PCV-2a NLS, PCV-
2b NES, and PCV-2b NLS were successfully isolated after amplification with PCR. 
 
 
 
 
 
 2 log 
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Figure 10. The Steps Required to Yield the Target Constructs for Sub-cellular Localization 
Experiments.  Localization experiments involving PCV-2b VP3 NES and PCV-2b VP3 NLS 
require the insertion of these genes into GFP vector.  Before the target constructs can be made, 
the truncation mutants (PCV-2b VP3 NES and PCV-2b NLS) must be created using PCR, ligated 
into pGEM T-vector, isolated form pGEM T-vector, then finally ligated into GFP vector. In this 
study, PCV-2b NES and PCV-2b NLS were successfully ligated into pGEM T-vector and 
subsequently isolated from it.  
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Figure 11.  Confirmation of pGEM T-Vector Constructs.  Lane 1: uncut plasmid; Lane 2: 
plasmid restricted with EcoRI and Bam HI.  A) Confirmation of pGEM T-vector construct with 
PCV-2b NES.  Note the faint PCV-2b NES insert band in Lane 2, as indicated with the black 
arrow.  B) Confirmation of pGEM T-vector construct with PCV-2b NLS.  Note the faint PCV-2b 
NLS insert band in Lane 2, as indicated with the black arrow. 
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Figure 12. PCV-2b VP3 (Full Sequence) and PCV-2b NES Nucleotide Alignment.  The 
nucleotide alignment of PCV-2b VP3’s PubMed sequence and the PCV-2b NES sequence that 
was cloned into pGEM T-vector. There is one nucleotide difference (position 89). 
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Figure 13. PCV-2b VP3 (Truncated Sequence) and PCV-2b NES Nucleotide Alignment.  
The nucleotide alignment of PCV-2b VP3’s PubMed sequence and the PCV-2b NES sequence 
that was cloned into pGEM T-vector. There is one nucleotide difference (position 89). 
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Figure 14. PCV-2b VP3 (Full Sequence) and PCV-2b NES Amino Acid Alignment.  The 
amino acid alignment of PCV-2b VP3 (derived from the PubMed nucleotide sequence and 
translated using CLC Workbench) and the PCV-2b NES amino acid sequence (derived from the 
pGEM T-vector nucleotide sequence and translated using CLC Workbench).  There is one amino 
acid difference (position 30). 
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Figure 15. PCV-2b VP3 (Truncated Sequence) and PCV-2b NES Amino Acid Alignment.  
The amino acid alignment of PCV-2b VP3 (derived from the PubMed nucleotide sequence and 
translated using CLC Workbench) and the PCV-2b NES amino acid sequence (derived from the 
pGEM -vector nucleotide sequence and translated using CLC Workbench).  There is one amino 
acid difference (position 30). 
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Figure 16. PCV-2b VP3 (Full Sequence) and PCV-2b NLS Nucleotide Alignment.  The 
nucleotide alignment of PCV-2b VP3’s PubMed sequence and the PCV-2b NLS sequence that 
was cloned into pGEM T-vector. There are two nucleotide differences (positions 304 and 310). 
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Figure 17.  PCV-2b VP3 (Truncated Sequence) and PCV-2b NLS Nucleotide Alignment.  
The nucleotide alignment of PCV-2b VP3’s PubMed sequence and the PCV-2b NLS sequence 
that was cloned into pGEM T-vector. There are two nucleotide differences (positions 111 and 
117). 
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Figure 18. PCV-2b VP3 (Full Sequence) and PCV-2b NLS Amino Acid Alignment.  The 
amino acid alignment of PCV-2b VP3 (derived from the PubMed nucleotide sequence and 
translated using CLC Workbench) and the PCV-2b NLS amino acid sequence (derived from the 
pGEM T-vector nucleotide sequence and translated using CLC Workbench).  There are two 
amino acid differences (positions 102 and 104). 
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Figure 19. PCV-2b VP3 (Truncated Sequence) and PCV-2b NLS Amino Acid Alignment.  
The amino acid alignment of PCV-2b VP3 (derived from the PubMed nucleotide sequence and 
translated using CLC Workbench) and the PCV-2b NLS amino acid sequence (derived from the 
pGEM T-vector nucleotide sequence and translated using CLC Workbench).  There are two 
amino acid differences (positions 38 and 40). 
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Figure 20. Cleavage of the Non-Fluorescent Caspase Substrate Z-DEVD-R110 by Caspase-
3/7 to Create the Fluorescent Rhodamine 110.   Effector caspases such as caspase-3 and 
caspase-7 will be activated by initiator caspases in apoptotic cells.  These caspases will go on to 
cleave other targets, such as the Z-DEVD-R110 substrate from the APO-ONE® Homogeneous 
Caspase-3/7 Assay Kit.  Upon cleavage of the DEVD peptides from Z-DEVD-R110, the leaving 
group Rhodamine 110 is produced.  Rhodamine 110 is an intensely fluorescent compound with 
an excitation wavelength of 499 nm and an emission wavelength of 521 nm. This fluorescence, 
therefore, can be measured and used as a means of assessing apoptotic activity.  
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Figure 21. PCV-2b VP3 Induces Apoptosis in Transformed Cells via a p53-Independent 
Pathway.  This data graphically shows the fluorescence emitted (λmax = 521 nm) after using 
Promega’s Apo-ONE® Homogeneous Caspase-3/7 Assay Kit.  This fluorescence is a direct 
measure of caspase-3/7 activity and thus, level of apoptosis.  PCV-2bVP3 induced apoptosis in 
H1299 cells (a p53-null cell line) as well as wild-type Apoptin (the positive control), whereas 
PCV-2a VP3 failed to induce apoptosis, just as the ‘no DNA’ control did.  Each sample was 
conducted in triplicate.  
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